The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Sildenafil ratiopharm sildenafil Generic | Ratiopharm GmbH | Erectile Dysfunction | 🇪🇺 EU 2009-12-23 | Order → |
| Olazax olanzapine Generic | Glenmark Pharmaceuticals s.r.o. | Schizophrenia; Bipolar Disorder | 🇪🇺 EU 2009-12-11 | Order → |
| Rivastigmine 1 A Pharma rivastigmine | 1 A Pharma GmbH | Alzheimer Disease; Dementia; Parkinson Disease | 🇪🇺 EU 2009-12-11 | Order → |
| Rivastigmine Hexal rivastigmine | Hexal AG | Dementia; Alzheimer Disease; Parkinson Disease | 🇪🇺 EU 2009-12-11 | Order → |
| Lamivudine Teva Pharma B.V. lamivudine Generic | Teva B.V. | HIV Infections | 🇪🇺 EU 2009-12-10 | Order → |
| Olazax Disperzi olanzapine Generic | Glenmark Pharmaceuticals s.r.o. | Schizophrenia; Bipolar Disorder | 🇪🇺 EU 2009-12-10 | Order → |
| Rivastigmine Sandoz rivastigmine | Sandoz GmbH | Dementia; Alzheimer Disease; Parkinson Disease | 🇪🇺 EU 2009-12-10 | Order → |
| Sildenafil Actavis sildenafil Generic | Actavis Group PTC ehf | Erectile Dysfunction | 🇪🇺 EU 2009-12-10 | Order → |
| Prevenar 13 pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) | Pfizer Europe MA EEIG | Pneumococcal Infections; Immunization | 🇪🇺 EU 2009-12-09 | Order → |
| Olanzapine Glenmark olanzapine Generic | Glenmark Arzneimittel GmbH | Schizophrenia; Bipolar Disorder | 🇪🇺 EU 2009-12-03 | Order → |
| Olanzapine Glenmark Europe olanzapine Generic | Glenmark Arzneimittel GmbH | Schizophrenia; Bipolar Disorder | 🇪🇺 EU 2009-12-03 | Order → |
| Hirobriz Breezhaler indacaterol | Novartis Europharm Limited | Pulmonary Disease, Chronic Obstructive | 🇪🇺 EU 2009-11-30 | Order → |
| Nevirapine Teva nevirapine Generic | Teva B.V. | HIV Infections | 🇪🇺 EU 2009-11-30 | Order → |
| Sildenafil Teva sildenafil Generic | Teva B.V. | Erectile Dysfunction | 🇪🇺 EU 2009-11-30 | Order → |
| Zutectra human hepatitis B immunoglobulin | Biotest Pharma GmbH | Immunization, Passive; Hepatitis B; Liver Transplantation | 🇪🇺 EU 2009-11-30 | Order → |
| Onbrez Breezhaler indacaterol | Novartis Europharm Limited | Pulmonary Disease, Chronic Obstructive | 🇪🇺 EU 2009-11-29 | Order → |
| Oslif Breezhaler indacaterol | Novartis Europharm Limited | Pulmonary Disease, Chronic Obstructive | 🇪🇺 EU 2009-11-29 | Order → |
| Irbesartan/Hydrochlorothiazide Teva irbesartan;hydrochlorothiazide Generic | Teva B.V. | Hypertension | 🇪🇺 EU 2009-11-26 | Order → |
| Multaq dronedarone | Sanofi Winthrop Industrie | Atrial Fibrillation | 🇪🇺 EU 2009-11-25 | Order → |
| Copalia HCT amlodipine;valsartan;hydrochlorothiazide | Novartis Europharm Limited | Hypertension | 🇪🇺 EU 2009-11-03 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.